{"id":"NCT00383721","sponsor":"Organon and Co","briefTitle":"Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)","officialTitle":"A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2006-10-03","resultsPosted":"2011-10-26","lastUpdate":"2024-05-23"},"enrollment":1196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Mometasone furoate/formoterol (MF/F) combination","otherNames":["SCH 418131"]},{"type":"DRUG","name":"Mometasone furoate/formoterol (MF/F) combination","otherNames":["SCH 418131"]},{"type":"DRUG","name":"Mometasone furoate MDI (MF MDI)","otherNames":["SCH 32088"]},{"type":"DRUG","name":"Formoterol MDI","otherNames":["Foradil"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"MF/F MDI 400/10 mcg BID","type":"EXPERIMENTAL"},{"label":"MF/F MDI 200/10 mcg BID","type":"EXPERIMENTAL"},{"label":"MF MDI 400 mcg BID","type":"EXPERIMENTAL"},{"label":"Formoterol MDI 10 mcg BID","type":"ACTIVE_COMPARATOR"},{"label":"Placebo MDI BID","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F MDI 200/10 mcg BID compared with MF 400 mcg BID and F 10 mcg BID in adults at least 40 years of age, with moderate to severe chronic obstructive pulmonary disease (COPD). All placebo-treated subjects and active-treated subjects who will not participate in the safety extension will be discontinued and will have their Final Visit at Week 26. Subjects who continue into the 26-week safety extension will have their Final Visit at Week 52. Efficacy will be measured by the mean change from Baseline to Week 13 in area under the forced expiratory volume in one second concentration time curve from 0 to 12 hours (FEV1 AUC\\[0-12hr\\]) and change from Baseline to Week 13 in AM predose FEV1.","primaryOutcome":{"measure":"Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)","timeFrame":"Baseline to Endpoint (13 weeks)","effectByArm":[{"arm":"MF/F MDI 400/10 mcg BID","deltaMin":1.189,"sd":0.408},{"arm":"MF/F MDI 200/10 mcg BID","deltaMin":1.195,"sd":0.408},{"arm":"MF MDI 400 mcg BID","deltaMin":1.26,"sd":0.408},{"arm":"F MDI 10 mcg BID","deltaMin":1.176,"sd":0.408},{"arm":"Placebo","deltaMin":1.205,"sd":0.408}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25044280","22334770","22334769"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":225},"commonTop":["Headache","Nasopharyngitis","Upper respiratory tract infection"]}}